Sana Biotechnology, Inc.
Sana Biotechnology, Inc. (SANA): 12 pipeline candidates · ~9 mo cash runway · 5 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
8.5 months
D/E 2.13 · 3% dilution
Lead: Approved
12 candidates
N/A
N/A
A transparent, data-derived signal for Sana Biotechnology, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$784.8M
Cash
$88.0M
Quarterly Burn
$37.4M
Runway
8.5 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (12 candidates)
| Drug | Phase |
|---|---|
| granisetron | Approved |
| granisetron | Approved |
| sana device | — |
| sana device | — |
| sc255 | Preclinical |
| sc262 | Phase 1 |
| sc291 | Phase 1 |
| sc379 | Preclinical |
| sc451 | Preclinical |
| sg293 | Preclinical |
Showing 10 of 12 candidates. Sign up for full pipeline.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
198
Total value held
$471.2M
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 37,430,284 | $107.8M |
| flagship pioneering, llc | 25,001,856 | $72.0M |
| vanguard capital management llc | 14,869,448 | $42.8M |
| blackrock, inc. | 14,240,175 | $41.0M |
| state street corp | 10,538,086 | $30.3M |
| canada pension plan investment board | 10,221,900 | $29.4M |
| geode capital management, llc | 4,181,973 | $12.0M |
| marex group plc | 3,999,100 | $11.5M |
| goldman sachs group inc | 3,181,115 | $9.2M |
| bank of america corp /de/ | 2,946,861 | $8.5M |
Showing top 10 of 198 institutional holders of Sana Biotechnology, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Sana Biotechnology, Inc.'s pipeline?
Sana Biotechnology, Inc. (SANA) has 12 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Sana Biotechnology, Inc.'s lead drug candidate?
Sana Biotechnology, Inc.'s most advanced tracked candidate is granisetron (Approved) for INDICATIONS AND USAGE Granisetron is indicated for the prevention of: Nausea and vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin. Nausea and vomiting associated with radiation, including total body irradiation and fractionated abdominal radiation..
What is Sana Biotechnology, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Sana Biotechnology, Inc. has approximately 8.5 months of cash runway.
What is Sana Biotechnology, Inc.'s market capitalization?
Sana Biotechnology, Inc.'s market capitalization is approximately $784.8M.
Who is the CEO of Sana Biotechnology, Inc.?
Dr. Steven D. Harr M.D. is the chief executive officer of Sana Biotechnology, Inc. (SANA).
Get the full picture on Sana Biotechnology, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.